BLOG

French Partnership Deploys AI for Antibody Drug Discovery

French companies OSE Immunotherapeutics and MAbSilico are teaming up to drive the discovery of new antibody drugs using artificial intelligence. The three-year partnership will use artificial intelligence, or AI, in six programs designed to accelerate the development of therapeutic monoclonal antibodies (mAbs) that can target cancer and autoimmune diseases.